All News

Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.

Pharmacists can identify medications and conditions that may augment or exacerbate constipation.

Data from conference abstracts and presentations indicate that both preexposure prophylaxis methods continue to demonstrate efficacy.

Treatment with ruxolitinib in patients with myelofibrosis and anemia was associated with more inpatient medical center and emergency department visits while increasing health care-related financial burdens compared with nonanemic patients.

David S. Bateshansky, PharmD, BCOP, discusses his role as an oncology pharmacist at USC Norris Comprehensive Cancer Center, noting the evolving recognition of pharmacists' contributions on cancer care teams.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

This marks steps toward improving health care pricing transparency, but further reforms are needed to reduce costs long-term.

Alcohol consumption, though typically associated with adverse health outcomes, could be associated with reduced low-density lipoprotein cholesterol (LDL-C) and improved high-density lipoprotein cholesterol (HDL-C).

Lipid metabolism plays a critical role in the function of T-cells.

The authors note that further research is needed to clarify cost-effectiveness, long-term adherence, and psychosocial impacts of oral immunotherapy.

Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs.

The new data emphasize the fundamental differences in management and associated complications with each form of diabetes.

Pharmacists with a deeper knowledge of xerostomia are ideally positioned to help educate patients with dry mouth on making informed self-care decisions for effective symptom management and improved quality of life.

Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.

The Western diet was associated with increased risk of lung cancer.

Some of these approaches for chronic kidney disease (CKD) include cystatin C, SGLT2 inhibitors, point-of-care testing in remote areas, and acid-lowering medications.

Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.

Reported terminations and limitations on research projects studying vaccine hesitancy and strategies to increase vaccine uptake are poised to greatly impact studies of the phenomenon.

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

This study found no significant difference in the sustained return of spontaneous circulation or survival to hospital discharge based on the timing of the first epinephrine administration in these patients.

Measures including disease-free survival and overall survival were improved in patients with MF who underwent hematopoietic stem cell transplantation (HSCT) and a 3D volumetric splenomegaly analysis.

Patients adhering to cagrilintide/semaglutide treatment experienced an average 15.7% weight loss.

Pharmacists are crucial in Elevidys administration, ensuring accurate dosing, coordinating treatment timing, and managing adverse effects to optimize patient outcomes.

Adults with asthma or COPD face a heightened risk of RSV-related illness.

Eculizumab, a humanized monoclonal antibody, was first approved for adults with generalized myasthenia gravis in 2017.

Untargeted lipidomics identified a glycerophospholipid and sphingolipid signature that differentiated severe alcohol-related hepatitis (sAH) from decompensated cirrhosis (DC).

A new free resource provides clear insights on contracted rates, enabling pharmacies to fill the community care gap.

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.